Under the revised IMWG diagnostic criteria, a subgroup of SMM at ultra-high risk for progression has been re-classified as multiple myeloma, increasing the number of patients who require treatment ...

Multiple myeloma is a rare blood cancer of the plasma cells in bone marrow -- the soft, spongy interior of bone where all blood cells are produced. Plasma cells are a type of white blood cell that ...

Fatigue, bone pain, and frequent infections can all be signs of the blood cancer multiple myeloma, which often has no early distinctive symptoms.

A new investigational treatment has shown strong and lasting responses in multiple myeloma patients with extramedullary disease (EMD), a particularly aggressive and difficult-to-treat form of the ...

A new form of immunotherapy is showing promising results for multiple myeloma patients in a study, an investigation found that crime-free lease addendums aren't reducing crime and increasing ...

Multiple myeloma bone lesions occur when cancerous cells cause the bones to form weak spots, which can lead to breaks. Learn more about lesions and pain.

The future of multiple myeloma treatment is personalised, but collaboration is essential to deliver it. Learn about the latest advancements and how working together can improve outcomes for patients.

Sanofi earns CHMP backing to expand Sarclisa's use for newly diagnosed multiple myeloma patients eligible for transplant.

Discover how driving innovation in multiple myeloma treatment can positively impact the patient experience. Stay informed on the latest advancements in cancer research and patient care.